Ocugen News - July 29, 2026

🔴 Ocugen is trading 5.2% down today on profit-taking and broader biotech sector weakness

Ocugen is trading at $1.18 (5.2% down) today as investors take profits following a recent rally sparked by FDA RMAT designation for its OCU410 gene therapy. •...

Ocugen Wins FDA RMAT Status for Blindness Gene Therapy, Accelerating Review

Ocugen received U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy candidate, OCU410. The...